These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9193342)

  • 21. Treatment of newly diagnosed state D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, intergroup study 0036.
    Crawford ED; Allen JA
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):961-3. PubMed ID: 2126738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
    Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E
    Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acute renal toxicity associated with suramin in the treatment of prostate cancer.
    Figg WD; Cooper MR; Thibault A; Headlee D; Humphrey J; Bergan RC; Reed E; Sartor O
    Cancer; 1994 Sep; 74(5):1612-4. PubMed ID: 8062193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Primary treatment for stage D2 prostate cancer: a randomized study of combined androgen blockade alone versus combined with UFT].
    Sumiyoshi Y; Hashine K; Kuwahara M; Aki M; Yamamoto A; Akazawa S; Takenaka A
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1153-8. PubMed ID: 10431581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer.
    Eisenberger MA; Sinibaldi VJ; Reyno LM; Sridhara R; Jodrell DI; Zuhowski EG; Tkaczuk KH; Lowitt MH; Hemady RK; Jacobs SC
    J Clin Oncol; 1995 Sep; 13(9):2174-86. PubMed ID: 7666076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Total androgen blockade: the United States experience.
    Benson RC
    Eur Urol; 1993; 24 Suppl 2():72-6. PubMed ID: 8262130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete androgen blockade versus chemical castration in advanced prostatic cancer: analysis of an Italian multicentre study. Italian Leuprorelin Group.
    Bono AV; DiSilverio F; Robustelli della Cuna G; Benvenuti C; Brausi M; Ferrari P; Gibba A; Galli L
    Urol Int; 1998; 60 Suppl 1():18-24. PubMed ID: 9563140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer.
    Macfarlane MT; Abi-Aad A; Stein A; Danella J; Belldegrun A; deKernion JB
    J Urol; 1993 Jul; 150(1):132-4. PubMed ID: 7685421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer.
    Kelly WK; Scher HI; Mazumdar M; Pfister D; Curley T; Leibertz C; Cohen L; Vlamis V; Dnistrian A; Schwartz M
    J Clin Oncol; 1995 Sep; 13(9):2214-22. PubMed ID: 7666079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Meluch AA; Spigel DR; Yost K; Meng C; Greco FA
    Clin Genitourin Cancer; 2006 Mar; 4(4):287-92. PubMed ID: 16729913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimation of total PSA with a supersensitive PSA-assay during neo-adjuvant-chemotherapy of prostate cancer before radical resection of prostate.
    Spitz J; Enzmann T; Müller W; Weidenfeld M; Köllermann M
    Anticancer Res; 1999; 19(4A):2637-40. PubMed ID: 10470209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.
    Rosen PJ; Mendoza EF; Landaw EM; Mondino B; Graves MC; McBride JH; Turcillo P; deKernion J; Belldegrun A
    J Clin Oncol; 1996 May; 14(5):1626-36. PubMed ID: 8622081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
    Hudes GR; Nathan F; Khater C; Haas N; Cornfield M; Giantonio B; Greenberg R; Gomella L; Litwin S; Ross E; Roethke S; McAleer C
    J Clin Oncol; 1997 Sep; 15(9):3156-63. PubMed ID: 9294479
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.
    Ellerhorst JA; Tu SM; Amato RJ; Finn L; Millikan RE; Pagliaro LC; Jackson A; Logothetis CJ
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2371-6. PubMed ID: 9815636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cryosurgery of prostate cancer. Use of adjuvant hormonal therapy and temperature monitoring--A one year follow-up.
    Lee F; Bahn DK; McHugh TA; Kumar AA; Badalament RA
    Anticancer Res; 1997; 17(3A):1511-5. PubMed ID: 9179188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of flutamide in hormone-refractory metastatic prostate cancer.
    McLeod DG; Benson RC; Eisenberger MA; Crawford ED; Blumenstein BA; Spicer D; Spaulding JT
    Cancer; 1993 Dec; 72(12 Suppl):3870-3. PubMed ID: 8252506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
    Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
    Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
    J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from a prospective study in men undergoing intermittent androgen suppression.
    Ng E; Woo HH; Turner S; Leong E; Jackson M; Spry N
    J Urol; 2012 Jun; 187(6):2162-6. PubMed ID: 22503022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.